“…Then, with the emergence of Covid-19, many libraries were screened on SARS-CoV-2 nsp14 but the inhibition results were rather poor [ [16] , [17] , [18] , [19] , [20] ]. In contrast, rational drug design approaches lead to the identification of much more potent inhibitors active at nanomolar [ [21] , [22] , [23] , [24] , [25] ] or subnanomolar concentration [ 25 ]. All these new inhibitors are mimics of SAM/SAH and most of them have been modeled in the crystal structure of SARS-CoV nsp14, solved in the presence of SAM (PDB 5C8T ) [ 26 ].…”